Epibrassinolide reduced lysate β-catenin levels and the expression of pathway target genes such as c-Myc, CCND1, Sox9, c-Jun, Survivin, MMP1, MMP7, and mPar in NCI-H69 and a multi-drug-resistant VPA17 small-cell lung carcinoma line. This evidence concerns the gene CCND1 and small cell lung carcinoma.